基本資料
種類: ETF
費用比率%: --
資產淨值: 24.69
成立日期: 16/09/2026
 
分析
市值分佈:
79.56%
大市值
15.76%
中市值
2.86%
小市值
持股比例加總可能不達100%,原因包括ETF持有現金或衍生工具。
 
 
行業分佈 國家/地區分佈
 
投資組合
 (更新時間: 07/11/2026 05:47) 總持有投資項目: 88  
0%
 
100%
     10大 (28.31%)
代號 名稱 佔比% ▼ 持有日期
PTGXProtagonist Therapeutics0.9931/10/2026
ROIVRoivant Sciences Ltd0.9831/10/2026
VERAVera Therapeutics0.9831/10/2026
IMVTImmunovant0.9231/10/2026
REGNRegeneron Pharmaceuticals0.9131/10/2026
COGTCogent Biosciences0.9031/10/2026
PVLAPalvella Therapeutics Inc0.8931/10/2026
XNCRXencor0.8731/10/2026
IDYAIDEAYA Biosciences0.8731/10/2026
REPLReplimune Group0.8631/10/2026
GILDGilead Sciences0.8530/09/2026
IONSIonis Pharmaceuticals0.8531/10/2026
ABSIAbsci Corp0.8331/10/2026
ORKAOruka Therapeutics Inc0.8231/10/2026
VCYTVeracyte0.8130/09/2026
SMMTSummit Therapeutics0.7631/10/2026
INCYIncyte Corp0.7431/10/2026
ASNDAscendis Pharma A/S0.7330/09/2026
STOKStoke Therapeutics0.6930/09/2026
TRAXFirst Tracks Biotherapeutics Inc.0.6631/10/2026
  1    2   3    4    5  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.